Abstract | Cilj ovog istraživanja bio je sistematično i podrobno istražiti učinke stabilnog pentadekapeptida
BPC 157 u interakciji s NO-spojevima u modelima psihoze i nuspojava antipsihotika na
štakorima.
Ukupno se koristilo 558 mužjaka štakora soja Wistar. U grupi akutnih pokusa koristilo se
ukupno 378 štakora i agensi su bili aplicirani jednokratno. U kroničnim pokusima koristilo se
ukupno 180 štakora. Pokusi su bili podijeljeni na akutne (motorna hiperaktivnost, katalepsija,
deficit pamćenja, negativni simptomi i intolerancija glukoze) i subkronične pokuse (socijalna
interakcija, lokomotorna senzibilizacija). U tako prikladnim modelima fokusirali smo se na
odnos učinaka BPC 157, L-NAME (NOS-inhibitor) i L-arginina (NOS-supstrat) prema
simptomima sličnim psihozi, koji su bili inducirani različitim agensima u dozama koje su
izazivale željeno ponašanje. Agensi (mg/kg intraperitonealno, i.p.) L-NAME (5,0), L-arginin
(100,0), BPC 157 (0,01), su davani sami i/ili zajedno, 5 minuta prije izazova akutnih
poremećaja motoričke aktivnosti (neizravni/izravni agonisti dopamina (amfetamin (3,0),
apomorfin (2,5)), nekompetitivni antagonist NMDA receptora (MK-801 (0,2)), katalepsije
(antagonist dopaminskih receptora haloperidol (2,0)), kognitivnog poremećaja (nekompetitivni
antagonist NMDA receptora (ketamin (3,0)), anksioznosti i anhedonije (nekompetitivni
antagonist NMDA receptora (ketamin (30,0)). U modelu socijalne interakcije (nekompetitivni
antagonist NMDA receptora (ketamin (8,0)) administriran je kroz 3 dana. Alternativno, BPC
157 (0,01) je administriran neposredno nakon L-NAME (40 mg/kg) i.p. Također, BPC 157 je
administriran neposredno prije bolusa glukoze (glukoza (1,0)) i antipsihotika olanzapina
(olanzapin (15,0) i 60 minuta nakon olanzapina. Da bismo inducirali ili spriječili senzibilizaciju,
koristili smo kroničnu administraciju metamfetamina u rastućoj dozi, naizmjenično 3 dana
tijekom prva 3 tjedana (metamfetamin (3,0 – 6,0 – 9,0), i izazov nakon sljedeća 4 tjedna
(metamfetamin (0,5) te lijekove (L- NAME, L-arginin, BPC 157) 5 minuta prije metamfetamina
u drugom i trećem tjednu. Dani sami, BPC 157 ili L-arginin su suzbili učinke inducirane
amfetaminom, apomorfinom i MK-801 u modelima psihoze, katalepsiju izazvanu
haloperidolom, poremećaj prostornog pamćenja induciran ketaminom, anksioznost (samo BPC
157) i anhedoniju induciranu ketaminom, te kroničnu senzibilizaciju induciranu
metamfetaminom. BPC 157 je smanjio socijalni deficit induciran ketaminom, dok je L-arginin
poništio korisni učinak L-NAME u tom testu. L-NAME nije utjecala na učinke izazvane
apomorfinom i MK-801, katalepsiju izazvanu haloperidolom, kroničnu senzibilizaciju izazvanu
metamfetaminom, deficit prostornog pamćenja izazvan ketaminom, pogoršala je anhedoniju, ali i suzbila akutni učinak amfetamina i socijalni deficit induciran ketaminom. U
kombinacijama (L-NAME + L-arginin), specifično za NO, L-NAME se suprotstavlja
antagonizaciji induciranoj s L-argininom kod apomorfinskih-, MK-801-, haloperidolskih-,
metamfetaminskih-, ali ne i kod amfetaminskih štakora. Za razliku od L-arginina, BPC 157
održava svoj protuučinak u prisutnosti NOS-blokade (L-NAME + BPC 157) ili prekomjerne
stimulacije NO-sustava (L-arginin + BPC 157). Ilustrirajući odnos BPC 157-L-arginina, BPC
157 je obnovio antagonizaciju (L-NAME + L-arginin + BPC 157) koja je ukinuta
koadministracijom L-NAME s L-argininom (L-NAME + L-arginin). BPC 157 je izravno
inhibirao katalepsiju izazvanu visokom dozom L-NAME. Napokon, BPC 157 je suzbio
hiperglikemiju induciranu bolusom glukoze i hiperglikemiju i katalepsiju izazvanu
olanzapinom.
Na temelju dobivenih rezultata može se zaključiti da postoje dvije karakteristične prezentacije
NO-puteva: antagonizam (suprotni učinci) ili sinergizam (paralelni učinci), gdje je učinak BPC
157 uvijek superiorniji. Sadašnja studija pruža eksperimentalne dokaze da je pentadekapeptid
BPC 157 djelotvoran u suzbijanju učinaka na ponašanje povezanih sa stimulacijom ili
blokadom dopaminskih receptora, blokadom NMDA receptora ili blokadom NO sustava što
ukazuje na funkcionalnu interakciju između ovog peptida i dopaminergičkog /
glutamatergičkog / nitrergičkog sustava. BPC 157 ima poseban modulacijski učinak, potreban
za održavanje pravilnog funkcioniranja nekoliko neurotransmitorskih sustava.
BPC 157 posjeduje posebno siguran profil, koji se prilično razlikuje od standardnih
farmakoloških sredstava. Zapravo, za razliku od neuroleptika i antidepresiva, BPC 157 ima
poseban kardioprotektivni i antiaritmički učinak, te kako je sada pokazno i antidijabetogeni
učinak. Temeljem validnosti korištenih modela na životinjama može se zaključiti da bi BPC
157 mogao igrati značajnu ulogu u regulaciji pozitivnih i negativnih simptoma, te kognitivnog
poremećaja u shizofreniji. |
Abstract (english) | The aim of this study was to systematically and in detail investigate the effects of stable
pentadecapeptide BPC 157 in interaction with NO-compounds in models of psychosis and
antipsychotic side effects in rats.
A total of 558 male Wistar rats were used. In the group of acute experiments, a total of
378 rats were used and the agents were administered once. A total of 180 rats were used in
chronic experiments. The trials were divided into acute (motor hyperactivity, catalepsy,
memory deficits, negative symptoms, and glucose intolerance) and subchronic trials (social
interaction, locomotor sensitization). In such suitable models, we focused on the ratio of the
effect of BPC 157, L-NAME (NOS inhibitor) and L-arginine (NOS substrate) to psychosis-like
symptoms, which were induced by different agents in doses that induced the desired behavior.
Agents (mg / kg intraperitoneally, i.p.) L-NAME (5.0), L-arginine (100.0), BPC 157
(0.01), were administered alone and / or together, 5 minutes before the onset of acute motor
impairment (indirect / direct dopamine agonists (amphetamine (3.0), apomorphine (2.5)), noncompetitive
NMDA receptor antagonist (MK-801 (0.2)), catalepsy (dopamine receptor
antagonist haloperidol (2.0)) , cognitive impairment (non - competitive NMDA receptor
antagonist (ketamine (3.0)), anxiety and anhedonia (non - competitive NMDA receptor
antagonist (ketamine (30.0)). In a social interaction model, a noncompetitive NMDA receptor
antagonist (ketamine (8.0)) was administered over 3 days. Alternatively, BPC 157 (0.01) was
administered immediately after L-NAME (40 mg / kg) i.p. Also, BPC 157 was administered
immediately before bolus glucose (glucose (1.0)) and the antipsychotic olanzapine (olanzapine
(15,0)) and 60 minutes after olanzapine. To induce or prevent sensitization, we used chronic
administration of methamphetamine in increasing doses, alternately 3 days during the first 3
weeks (methamphetamine) (3.0 - 6.0 - 9.0), and challenge after the next 4 weeks
(methamphetamine (0.5) and medications (L-NAME, L-arginine, BPC 157) 5 minutes before
methamphetamine in the second and third weeks.
Given alone, BPC 157 or L-arginine suppressed the effects induced by amphetamine,
apomorphine, and MK-801 in neurochemical models of psychosis, haloperidol-induced
catalepsy, ketamine-induced spatial memory imapairment, ketamine-induced anxiety (only
BPC 157) and anhedonia, and chronic methamphetamine induced sensitisation. BPC 157 reduced the ketamine-induced social deficit, while L-arginine nullified the beneficial effect of
L-NAME in that test. L-NAME did not affect the effects caused by apomorphine and MK-801,
catalepsy caused by haloperidol, chronic sensitization caused by methamphetamine, spatial
memory deficit caused by ketamine, worsened anhedonia, but also suppressed the acute effect
of amphetamine and social deficit induced by ketamine. In combinations (L-NAME + Larginine),
specific for NO, L-NAME counteracts L-arginine-induced antagonism in
apomorphine-, MK-801-, haloperidol-, methamphetamine- and ketamine rats, but not in
amphetamine- rats. Unlike L-arginine, BPC 157 maintains its counter-effect in the presence of
NOS blockade (L-NAME + BPC157) or overstimulation of the NO system (L-arginine +
BPC157). Illustrating the relationships of BPC 157-L-arginine, BPC 157 restored the
antagonism (L-NAME + L-arginine + BPC157) which was abolished by co-administration of
L-NAME with L-arginine (L-NAME + L-arginine). BPC 157 directly inhibited high-dose LNAME-
induced catalepsy. Finally, BPC 157 suppressed bolus glucose-induced hyperglycemia
and olanzapine-induced hyperglycemia and catalepsy.
Based on the obtained results, it can be concluded that there are two characteristic
presentations of NO-pathways: antagonism (opposite effects) or synergism (parallel effects),
where the effect of BPC 157 is always superior. The present study provides experimental
evidence that the pentadecapeptide BPC 157 is effective in suppressing behavioral effects
associated with stimulation or blockade of dopamine receptors, blockade of NMDA receptors,
or blockade of the NO system suggesting a functional interaction between this peptide and the
dopaminergic / glutamatergic / nitrergic system. BPC 157 has a special modulating effect,
required to maintain the proper functioning of several neurotransmitter systems.
BPC 157 has a particularly safe profile, which is quite different from standard
pharmacological agents. In fact, unlike neuroleptics and antidepressants, BPC 157 has
particular cardioprotective and antiarrhythmic effects, and now shown also antidiabetogenic
effect. Based on the validity of the animal models used, it can be concluded that BPC 157 could
play a significant role in the regulation of positive and negative symptoms, and cognitive
impairment in schizophrenia. |